Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis

被引:33
作者
Ho, SA
Ball, R
Morrison, LJ
Brownlee, KG
Conway, SP
机构
[1] St James Univ Hosp, Childrens Day Hosp, Leeds Reg Paediat Cyst Fibrosis Unit, Leeds LS9 7TF, W Yorkshire, England
[2] Univ Leeds, Dept Paediat, Leeds, W Yorkshire, England
关键词
cystic fibrosis; hypertonic saline induction; cough swab; sputum;
D O I
10.1002/ppul.20035
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Prompt detection and treatment of lower respiratory tract infection are essential in the management of patients with cystic fibrosis (CF), who often have signs or symptoms of respiratory infection without any pathogens being isolated from sputum or cough swab specimens. The aims of this study were to assess the efficacy and clinical value of obtaining sputum and oropharyngeal cough swab samples following induction with hypertonic saline (HS) in this group of patients. Forty-three outpatients with CF, mean age 7.2 years (range, 1.8-12.9 years), were recruited over a 2-year period. Nebulized salbutamol was administered, followed by 6% HS. Sputum was preferentially obtained before and after HS induction if possible. If the patient was not able to expectorate, oropharyngeal cough swabs were taken instead. Four patients were able to expectorate sputum before and 19 after HS induction. The procedure was tolerated in 41 of 43 patients. Pathogens were isolated from 13 patients' HS-induced samples, but not from their corresponding preinduced specimens, and 4 patients' preinduced specimens cultured organisms which were not identified from their HS-induced samples. Significant changes were made in the management of 13 (30.2%) patients directly resulting from the positive culture of pathogens only from HS-induced samples. Cultures from oropharyngeal cough swab or expectorated sputum specimens following inhalation of HS provide additional microbiological information which is of clinical value and may lead to changes in patient management. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 25 条
[1]  
Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.3.CO
[2]  
2-G
[3]   CHANGING SUSCEPTIBILITY OF PSEUDOMONAS-AERUGINOSA ISOLATES FROM CYSTIC-FIBROSIS PATIENTS WITH THE CLINICAL USE OF NEWER ANTIBIOTICS [J].
BOSSO, JA ;
ALLEN, JE ;
MATSEN, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :526-528
[4]   Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis [J].
Bradley, J ;
McAlister, O ;
Elborn, S .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (04) :712-715
[5]   A COMPARISON OF ALBUTEROL ADMINISTERED BY METERED-DOSE INHALER (AND HOLDING CHAMBER) OR WET NEBULIZER IN ACUTE ASTHMA [J].
COLACONE, A ;
AFILALO, M ;
WOLKOVE, N ;
KREISMAN, H .
CHEST, 1993, 104 (03) :835-841
[6]  
Daly LE., 2000, INTERPRETATION USES, V5th ed
[7]   Sputum induction in young cystic fibrosis patients [J].
De Boeck, K ;
Alifier, M ;
Vandeputte, S .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (01) :91-94
[8]   Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis [J].
Emerson, J ;
Rosenfeld, M ;
McNamara, S ;
Ramsey, B ;
Gibson, RL .
PEDIATRIC PULMONOLOGY, 2002, 34 (02) :91-100
[9]   Use of cough swabs in a cystic fibrosis clinic [J].
Equi, AC ;
Pike, SE ;
Davies, J ;
Bush, A .
ARCHIVES OF DISEASE IN CHILDHOOD, 2001, 85 (05) :438-439
[10]  
Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO